Semaglutide / Glycine
A compounded semaglutide and glycine injection prescribed after a provider evaluation as part of a medically supervised weight program. It is not FDA approved.
Compounded drugs are not FDA approved. FDA does not review compounded drugs for safety, effectiveness, or quality before marketing.
See it before your first visit
Photographs of the medication as dispensed.
What it is
Semaglutide / Glycine is a compounded injection that combines semaglutide, a GLP-1 receptor agonist, with glycine, an amino acid. It is prescribed by a licensed provider as part of a medically supervised weight program.
It is a compounded medication. It is not FDA approved, and the FDA has not evaluated it for safety, effectiveness, or quality.
How it works
Semaglutide mimics a hormone called GLP-1 that affects appetite and digestion. Glycine is an amino acid. Human evidence for adding glycine to semaglutide is limited. Your provider will explain the dose, how it is increased over time, and how to inject it.
What to expect
Many prescribers start at a low dose and increase it gradually. Nausea, constipation, and diarrhea are common, especially after a dose change. Your provider will review your progress at follow-ups. Results vary and no outcome is guaranteed.
Who it is for
This injection is prescribed by a licensed provider after an evaluation. It is not appropriate for everyone. Tell your provider if you or a family member has had medullary thyroid carcinoma or MEN 2, or if you have pancreatitis, gallbladder disease, kidney disease, diabetes, or are pregnant or breastfeeding.
Side effects
Common side effects include nausea, vomiting, diarrhea, constipation, stomach pain, and tiredness. Serious effects can include pancreatitis, gallbladder problems, kidney injury from dehydration, and allergic reactions. Contact your provider if you have severe stomach pain, a lump or swelling in your neck, trouble swallowing, or signs of an allergic reaction.
Read this before you start
Compounded drugs are not FDA approved. FDA does not review compounded drugs for safety, effectiveness, or quality before marketing.
Medication availability, formulation, packaging and pharmacy fulfillment vary based on the patient's prescription and location.
Compounded medication. This medication is compounded by a pharmacy for an individual patient. It is not FDA approved, and the FDA has not evaluated it for safety, effectiveness, or quality.
Boxed warning, thyroid C-cell tumors. Semaglutide medications carry a boxed warning for risk of thyroid C-cell tumors. Do not use if you or a family member has had medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Other risks. Pancreatitis, gallbladder disease, kidney problems, low blood sugar when used with insulin or sulfonylureas, and diabetic retinopathy changes are possible. Tell your provider before any procedure that uses anesthesia or sedation.
Limited evidence. Human evidence for adding glycine is limited.
Pregnancy. Do not use if you are pregnant or planning to become pregnant.
Injection safety. Use a new sterile needle each time, rotate sites, and dispose of sharps safely. Do not share needles or vials.
This page is for general information and is not medical advice.
Common questions
Is Semaglutide / Glycine FDA approved?
No. It is a compounded medication. The FDA has not evaluated it for safety, effectiveness, or quality.
What is in it?
Semaglutide and glycine.
How is it given?
As a subcutaneous injection, following your provider's directions.
What are the common side effects?
Nausea, vomiting, diarrhea, and constipation are the most common.
%20(1)%20(1)%20(1).png)